ANIX:NSD-Anixa Biosciences, Inc (USD)

COMMON STOCK | Diagnostics & Research | NSD

Last Closing Price

USD 3.95

Change

0.00 (0.00)%

Market Cap

USD 0.12B

Volume

0.20M

Average Target Price

USD 11.00 (+178.48%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain viral protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with MolGenie GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was founded in 1982 and is based in San Jose, California.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-06-20 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ILMN Illumina, Inc

N/A

USD66.60B 106.58 59.22
IDXX IDEXX Laboratories, Inc

N/A

USD51.26B 77.35 58.22
DXCM DexCom, Inc

N/A

USD40.45B 80.36 99.58
EXAS Exact Sciences Corporation

N/A

USD21.70B N/A N/A
OZON Ozon Holdings PLC

N/A

USD12.20B N/A N/A
GH Guardant Health, Inc

N/A

USD12.15B N/A N/A
ICLR ICON Public Limited Company

N/A

USD11.22B 33.41 23.63
PRAH PRA Health Sciences, Inc

N/A

USD10.83B 51.13 26.42
NTRA Natera, Inc

N/A

USD9.05B N/A N/A
SYNH Syneos Health, Inc

N/A

USD8.72B 45.02 22.32

ETFs Containing ANIX

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Diagnostics & Research)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 28.66% 70% C- 76% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 28.66% 70% C- 75% C
Trailing 12 Months  
Capital Gain 64.58% 56% F 70% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 64.58% 56% F 69% D+
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 1.49% 31% F 33% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 1.49% 29% F 27% F
Risk Return Profile  
Volatility (Standard Deviation) 56.86% 54% F 31% F
Risk Adjusted Return 2.62% 27% F 24% F
Market Capitalization 0.12B 25% F 22% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Diagnostics & Research)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 3.30 65% D 45% F
Price / Cash Flow Ratio 2,965.71 3% F 1% F
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -45.31% 33% F 23% F
Return on Invested Capital -142.58% 5% F 4% F
Return on Assets -25.36% 26% F 14% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 4.64 46% F 35% F
Short Percent 2.69% 80% B- 58% F
Beta 1.42 34% F 31% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive cash flow

The company had positive total cash flow in the most recent four quarters.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector